These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38824624)

  • 1. The potential role of real-world evidence in Centers for Medicare & Medicaid Services' future price negotiations: Recommendations for a robust framework.
    Jaksa A; Arena PJ
    J Manag Care Spec Pharm; 2024 Jun; 30(6):604-607. PubMed ID: 38824624
    [No Abstract]   [Full Text] [Related]  

  • 2. Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.
    Jaksa A; Arena PJ; Gatto N
    J Comp Eff Res; 2023 Nov; 12(11):e230125. PubMed ID: 37815792
    [No Abstract]   [Full Text] [Related]  

  • 3. The Centers for Medicare & Medicaid Services' Overhaul of Office-Visit Payments-What's the Bottom Line for Otolaryngology?
    Rathi VK; Varvares MA; Naunheim MR
    JAMA Otolaryngol Head Neck Surg; 2019 Apr; 145(4):303-304. PubMed ID: 30730534
    [No Abstract]   [Full Text] [Related]  

  • 4. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
    Berkemeier F; Whaley C; Robinson JC
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Has the Centers for Medicare & Medicaid Services Implicitly Adopted a Value Framework for Medicare Drug Price Negotiations?
    Sullivan SD; Hernandez I; Ramsey SD; Neumann PJ
    Value Health; 2023 Dec; 26(12):1686-1688. PubMed ID: 37871678
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare Drug Pricing Negotiations: Assessing Constitutional Structural Limits.
    White EN; Saxon M; Hodge JG; Michaels J
    J Law Med Ethics; 2023; 51(4):956-960. PubMed ID: 38477275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare and Medicaid: passage, implementation, and societal ramifications.
    Nelson BA
    J Pediatr Ophthalmol Strabismus; 2002; 39(5):262-7. PubMed ID: 12353897
    [No Abstract]   [Full Text] [Related]  

  • 9. CMS Rule Would Increase Cost Transparency of Medicaid-Covered Drugs.
    Harris E
    JAMA; 2023 Jun; 329(24):2118. PubMed ID: 37285174
    [No Abstract]   [Full Text] [Related]  

  • 10. Is It Working? Evaluating The First Round Of Medicare Drug Price Negotiations.
    Tollen L
    Health Aff (Millwood); 2024 Sep; 43(9):1206-1208. PubMed ID: 39137362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One pill, many prices: variation in prescription drug prices in selected government programs.
    Gencarelli DM
    Issue Brief George Wash Univ Natl Health Policy Forum; 2005 Aug; (807):1-20. PubMed ID: 16167399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why the US Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting.
    Abbott AL; Adelman MA; Alexandrov AV; Barnett HJ; Beard J; Bell P; Björck M; Blacker D; Buckley CJ; Cambria RP; Comerota AJ; Connolly ES; Davies AH; Eckstein HH; Faruqi R; Fraedrich G; Gloviczki P; Hankey GJ; Harbaugh RE; Heldenberg E; Kittner SJ; Kleinig TJ; Mikhailidis DP; Moore WS; Naylor R; Nicolaides A; Paraskevas KI; Pelz DM; Prichard JW; Purdie G; Ricco JB; Riles T; Rothwell P; Sandercock P; Sillesen H; Spence JD; Spinelli F; Tan A; Thapar A; Veith FJ; Zhou W
    Angiology; 2012 Nov; 63(8):639-44. PubMed ID: 22495879
    [No Abstract]   [Full Text] [Related]  

  • 13. Centers for Medicare & Medicaid Services' Comprehensive Care for Joint Replacement: The Present and Future for Orthopedic Surgeons.
    Hogan CA; Sandoval MF; Uhler LM
    Orthopedics; 2017 Mar; 40(2):77-80. PubMed ID: 28339001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a rational, value-based drug benefit for Medicare.
    Lopert R; Moon M
    Health Aff (Millwood); 2007; 26(6):1666-73. PubMed ID: 17978385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates of the Number of Brand-name Drugs Affected by the Medicaid Rebate Cap in 2017.
    Dickson S
    JAMA Intern Med; 2019 Mar; 179(3):437-439. PubMed ID: 30667469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1).
    Pepper DJ; Natanson C; Eichacker PQ
    Ann Intern Med; 2018 Apr; 168(8):610-612. PubMed ID: 29543952
    [No Abstract]   [Full Text] [Related]  

  • 17. Sidebar: CMS seeks to fix Medicaid best-price barriers in value-based contracting for high-cost therapies in Medicaid.
    Caffrey M
    Am J Manag Care; 2020 Aug; 26(7 Spec No.):SP218-SP219. PubMed ID: 32840974
    [No Abstract]   [Full Text] [Related]  

  • 18. Considerations and recommendations for hand surgeons in light of Centers for Medicare and Medicaid Services price transparency rulings.
    Paidisetty PS; Shin A; Wang LK; Chen W
    J Plast Reconstr Aesthet Surg; 2024 Mar; 90():19-20. PubMed ID: 38335871
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 20. Use these 5 tips to mitigate exposure when assuming risk for Medicare pharmacy.
    Public Sect Contract Rep; 1999 Apr; 5(4):55-6, 49. PubMed ID: 10387741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.